Coronavirus Disease (COVID-19)
General Approach to Treatment

General Approach to Treatment

Remdesivir

Remdesivir is the 1st line agent for all patients with a SpO2 ≤94% who meet our eligibility criteria

Dexamethasone

  • Dexamethasone 6mg po/IV daily for up to 10 days is recommended for patients who are mechanically ventilated and may be considered for those with worsening hypoxia on any supplemental O2.

  • Steroids are not recommended for patients who do not require supplemental oxygen.

Other Agents

All other therapeutic agents at this time remain experimental.

Inpatient and Outpatient Trials

For a list of open inpatient and outpatient trials, please see this website.

DHHS Guidance